Is retatrutide legal to compound now? What the HHS peptide policy actually says

By · Published

Four small clear glass vials with dark caps on a steel tray next to a closed navy binder on a pharmacy workbench in soft window light.

Your feed this week probably had a version of it: "Compounding approved!" sitting under a photo of a vial, and a comment below asking whether that means retatrutide, the triple-hormone weight-loss drug everyone's been talking about since Lilly's trial results in May. It's a fair question. HHS really did open a compounding path for some peptides on October 28. Retatrutide isn't one of them.

Facts are as of October 29, 2026. Sources, with retrieval dates, are at the bottom.

Updated October 29, 2026. Lilly's new head-to-head trial against Ozempic, reported October 28, doesn't change any of this: retatrutide is still investigational, outside the HHS policy, and not eligible for compounding. Lilly's release adds that anyone selling it to consumers "is breaking the law." Trial details: retatrutide vs. Ozempic. [V]

The gist

  • On October 28, 2026, HHS released an enforcement discretion policy for 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry compounding of six peptides: BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. [V]
  • Retatrutide is not on that list. FDA's own GLP-1 page still says retatrutide "cannot be used in compounding under federal law." [V]
  • Nothing in the HHS notice is an FDA approval of any drug. Retatrutide remains investigational, and Lilly has said it plans to file for US approval in the first quarter of 2027. [V]
  • The excitement behind the confusion is real: retatrutide posted some of the largest weight-loss results yet seen in a phase 3 obesity program. [V]
  • 6peptides named in the HHS policy, none of them retatrutide [V]
  • 0federal compounding routes open to retatrutide today [V]
  • Q1 2027when Lilly says it plans to submit retatrutide to FDA [V]

What happened on October 28

HHS filed a notice titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" with the Federal Register. It went on public inspection October 28 and is scheduled to publish October 30, 2026, with a two-week comment window. [V] Signed by Health Secretary Robert F. Kennedy Jr., it says HHS won't go after pharmacies licensed by a state, federal facilities or licensed doctors who compound six named peptides under ten conditions. [V]

Those six are BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. [V] Reuters described it as letting licensed compounders work with "certain unapproved peptides" while regulators decide whether to permit them formally. [S] Law firm BakerHostetler's summary lists the same six and notes the policy doesn't cover 503BSection of federal drug law for outsourcing facilities: larger compounders that register with FDA and must follow drug-manufacturing quality rules. Glossary entry outsourcing facilities or products sold as research chemicals. [S]

We walk through the full text, the conditions and the timeline in our HHS interim policy breakdown.

Where retatrutide fits, and why it doesn't

Here's the part the headlines skipped. A pharmacy compounding under section 503A can use a bulk ingredient only if it meets a USP or NF monograph, already sits inside an FDA-approved drug, or appears on FDA's 503A bulks list. [V] FDA spelled out in a March 31, 2025 letter to the National Association of Boards of Pharmacy that retatrutide clears none of those bars, and that it isn't on the 503B bulks list or tied to a drug shortage either. [V] NABP forwarded that letter to state boards on April 3, 2025, describing compounding with retatrutide as prohibited under both 503A and 503B. [V]

The October 28 policy doesn't change that. It reaches only the six peptides in its Appendix A. [V] FDA's page on unapproved GLP-1 drugs, checked October 29, 2026, still carries a heading that reads "Retatrutide and cagrilintide cannot be used in compounding." [V]

“Retatrutide and cagrilintide cannot be used in compounding under federal law.” [V]

FDA, Concerns with Unapproved GLP-1 Drugs

There's also a structural reason retatrutide sits apart from the six. Those peptides had been nominated for the 503A bulks list and reviewed by FDA's Pharmacy Compounding Advisory Committee in July 2026. [V] Retatrutide is a drug in late-stage development by one company, which has said it's preparing a full application to FDA. [V] It's on a different road entirely: the approval road.

The enforcement record so far

FDA has acted against retatrutide sellers for more than a year. In a September 9, 2025 warning letter to one online seller, FDA called its compounded retatrutide products "unapproved new drugs and misbranded drugs" and walked through why they failed both 503A and 503B. [V] FDA's GLP-1 page lists warnings sent to telehealth firms over retatrutide marketing, ingredient distributors for selling it to compounders, and outsourcing facilities for repackaging it. [V] A JAMA news report tallied 21 FDA warning letters involving these unapproved GLP-1 drugs dating back to December. [S]

Lilly's position is just as plain. The company says retatrutide "has not been approved by any regulatory agency" and is legally available only through its clinical trials. [V] For what "research use only" labels mean legally, see our research-use-only label decoder.

What people get wrong

"HHS approved compounding for peptides, so retatrutide counts." The policy names six peptides and no others. Retatrutide isn't one. [V]

"Enforcement discretion means FDA approved them." HHS's own text says compounded drugs aren't FDA-approved and get no FDA review of safety, effectiveness or quality before sale. [V]

"Retatrutide is a GLP-1, and compounded GLP-1s were allowed during the shortage." The shortage-era compounding involved semaglutide and tirzepatide, which are components of approved drugs. Retatrutide has never been part of an approved drug. [V]

Telehealth firms and med spas are marketing it too; see what FDA and Lilly say about telehealth retatrutide offers.

Why so many people want it

The interest makes sense once you look at the data. In TRIUMPH-1, Lilly's first phase 3 obesity trial, the highest-dose group lost an average of 28.3% of body weight over 80 weeks against 2.2% on placebo, by Lilly's efficacy estimand, in a randomized, double-blind study of 2,339 adults. [V] In the trial's extension for people starting with a BMI of 35 or more, the average reached 30.3% at 104 weeks, a range Lilly noted has long been associated with bariatric surgery. [V] Two more phase 3 trials, TRIUMPH-2 in type 2 diabetes and TRIUMPH-3 in people with cardiovascular disease, were reported as successful on July 23, 2026. [V]

That's why the name travels so fast. We cover the trials, the mechanism and the regulatory road in depth in our retatrutide explainer.

Limits and unknowns

  • Every efficacy figure above comes from Lilly-funded trials, reported through Lilly releases and, for TRIUMPH-1, a peer-reviewed paper. Full TRIUMPH-2 and TRIUMPH-3 papers weren't out when we checked. [V]
  • Side effects in the trials were mostly gastrointestinal, and Lilly reported the lowest-dose group stopped for adverse events less often than placebo. [V] A longevitydocs summary put the highest-dose rate at 11.3% against 4.9% on placebo. [S]
  • Products sold online as retatrutide aren't Lilly's drug. Lilly warns they "may contain unknown ingredients, harmful contaminants and impurities." [V]
  • The HHS policy itself is interim. HHS says it may revise or withdraw it if safety or quality problems appear, and the final wording could change after comments. [V]
  • We haven't seen any federal signal that retatrutide will be added to a compounding list. [U]

Peptide Policy Watch

Is retatrutide legal to compound now? What the HHS peptide policy actually says

Published October 29, 2026 · https://peptidepolicywatch.com/2026/10/29/retatrutide-compounding-hhs-peptide-policy-what-changed/

Printable checklist

Questions for your clinician

General questions drawn from this page, to take to a clinician or pharmacist who knows your health history.

  1. Is the product you're being offered an FDA-approved drug, a legally compounded one, or neither?
  2. Which section of federal law, 503A or 503B, is the pharmacy compounding under?
  3. If something is labeled retatrutide, where does it come from, given that Lilly says it's only in trials?

Print view Select it, then use your browser’s Print command to print only this box.

What to watch next

Retatrutide and compounding: dates ahead

  1. Oct. 30, 2026HHS peptide policy scheduled to publish in the Federal Register [V]
  2. About Nov. 13, 2026Comment window on the HHS policy closes [V]
  3. Q1 2027Lilly's planned US submission for retatrutide [V]
  4. No date setAny FDA decision on a retatrutide application [V]

For the wider GLP-1 picture, start with our guide to approved, compounded and research-labeled GLP-1s and the compounding categories explainer. We'll update this page if FDA or HHS changes retatrutide's status.

Sources (retrieved October 29, 2026 unless noted)

  1. HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," with Appendix A and B [V] — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  2. Federal Register, public inspection document 2026-22192, scheduled to publish October 30, 2026 [V] — https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  3. FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" [V] — https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  4. FDA letter to NABP, March 31, 2025, forwarded by NABP to state boards April 3, 2025 (via Ohio Board of Pharmacy) [V] — https://www.pharmacy.ohio.gov/documents/pubs/special/compounding/fda%20letter%20-%20retatrutide%20in%20compounded%20drug%20products.pdf
  5. FDA warning letter, ASN-LABS, MARCS-CMS 716459, September 9, 2025 [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-716459-09092025
  6. Eli Lilly, "What to know about retatrutide" [V] — https://www.lilly.com/news/stories/what-to-know-about-retatrutide
  7. Eli Lilly, TRIUMPH-1 topline release, May 21, 2026 [V] — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
  8. Eli Lilly, TRIUMPH-2 and TRIUMPH-3 release, July 23, 2026 [V] — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
  9. BakerHostetler, "HHS Issues Enforcement Discretion Policy...," October 28, 2026 [S] — https://www.bakerlaw.com/insights/hhs-issues-enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances/
  10. Reuters via Investing.com, "US Health Secretary Kennedy opens access to some unapproved peptides," October 28, 2026 [S] — https://www.investing.com/news/general-news/us-health-department-to-allow-temporary-sale-of-some-unapproved-peptides-4980278
  11. JAMA, "Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain" [S] — https://jamanetwork.com/journals/jama/fullarticle/2855339
  12. longevitydocs News, "FDA sends an interim peptide compounding policy to White House review" [S] — https://news.longevitydocs.org/policy/fda-interim-peptide-compounding-policy-oira-review-bpc-157-retatrutide
  13. Eli Lilly, "Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial," October 28, 2026 [V] — https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits